932
Views
88
CrossRef citations to date
0
Altmetric
Original Article

Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser

Pages 2-5 | Received 20 Nov 2010, Accepted 26 Dec 2010, Published online: 21 Jan 2011
 

Abstract

Onychomycosis is a common disorder of the nails. Treatment modalities include oral and topical antifungals, surgical treatment or a combination of these therapies. Cure rates remain low with relatively high relapse rates seen after successful treatment. The purpose of this study was to evaluate the treatment of onychomycosis using a novel 0.65-millisecond (ms) pulsed 1064-nm laser. Eight subjects were treated over two to three sessions spaced at least 3 weeks apart. Of the eight subjects evaluated, seven had negative post-treatment cultures after the second or third session. Treatments were well tolerated by all subjects. These data suggest that treatment of onychomycosis with a 0.65-ms pulsed Nd:YAG 1064-nm laser should be studied further to determine the long-term clinical and microbiologic effect. The optimal number of treatment sessions for each patient needs to be determined.

Acknowledgements

Joe Hurley is acknowledged for his assistance with preparation of the manuscript.

Declaration of interest: The author reports no conflicts of interest. The author alone is responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.